Overview

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

Status:
Terminated
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
Phase II trial of AZD2014 in RICTOR amplified or overexpressed GC patients as second-line chemotherapy AZD2014 50mg BD continuous schedule of a 28 day cycle
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center